| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medical Laboratory Technology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Diagnostic performance of Liver FibraChek Dx©, a blood-based test for the non-invasive detection of liver cirrhosis and cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Fernando Siguencia, Michitaka Matsuda, Vijay Pandyarajan, Sunao Tanaka, Steven M Smith, Catherine Bresee, Ekihiro Seki, Charles J Rosser and Hideki Furuya |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hideki Furuya, Associate Professor, PhD, Department of Biomedical Science, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, United States. hideki.furuya@cshs.org |
| Key Words |
Biomarkers; Metabolic dysfunction-associated steatotic liver disease; Cirrhosis; Multiplex; Metabolomics; Peripheral blood; Hepatocellular carcinoma; Fibrosis; High pressure liquid chromatography |
| Core Tip |
This retrospective observational study assessed the diagnostic accuracy of Liver FibraChek Dx©, a non-invasive serum assay for detecting metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC). The test algorithm integrates five serum biomarkers and age to produce a risk score. Among 45 participants with biopsy-confirmed diagnoses (MASLD, HCC, or healthy), Liver FibraChek Dx© achieved an area under the receiver operating characteristic curve of 0.890, with 93.9% sensitivity and 88.9% accuracy. Risk scores significantly distinguished individuals with liver disease from healthy controls. These findings support the potential clinical utility of Liver FibraChek Dx© in diagnosing and monitoring liver pathogenesis via blood-based testing. |
| Publish Date |
2025-06-26 07:27 |
| Citation |
<p>Siguencia F, Matsuda M, Pandyarajan V, Tanaka S, Smith SM, Bresee C, Seki E, Rosser CJ, Furuya H. Diagnostic performance of Liver FibraChek Dx©, a blood-based test for the non-invasive detection of liver cirrhosis and cancer. <i>World J Hepatol</i> 2025; 17(6): 106481</p> |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i6/106481.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i6.106481 |
